Amitriptyline/oxymetazoline/ketoprofen

Drug Profile

Amitriptyline/oxymetazoline/ketoprofen

Alternative Names: Ketoprofen/amitriptyline/oxymetazoline; Ketoprofen/oxymetazoline/amitriptyline; OMS 103; OMS-103-HP; Oxymetazoline/amitriptyline/ketoprofen

Latest Information Update: 03 Aug 2015

Price : $50

At a glance

  • Originator Omeros Corporation
  • Class Dibenzocycloheptenes; Imidazoles; Nonsteroidal anti-inflammatories; Phenylpropionates; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor agonists; Alpha 2 adrenergic receptor agonists; Lipoxygenase-cyclooxygenase inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Postoperative pain

Most Recent Events

  • 03 Aug 2015 Amitriptyline/oxymetazoline/ketoprofen is still in phase III development for Postoperative pain
  • 17 Jun 2015 OMS 103HP licensed to Fagron in USA
  • 27 Dec 2012 Efficacy and adverse events data from a phase III trial in Postoperative pain released by Omeros Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top